产品
编 号：F076273
分子式：C17H14Br3N5OS
分子量：576.1
分子式：C17H14Br3N5OS
分子量：576.1
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1217022-63-3
产品详情
生物活性：
PTC-209 hydrobromide is a specific BMI-1 inhibitor with an IC50 of 0.5 μM in HEK293T cell line. PTC-209 hydrobromide irreversibly impairs colorectal cancer-initiating cells (CICs). PTC-209 hydrobromide shows potent anti-myeloma activity and impairs the tumor microenvironment.
体内研究：
PTC-209 (60 mg/kg body weight; subcutaneously; once a day for 11 days) significantly reduces tumor volume.Animal Model:Nude mice (male, aged 8-10 weeks, HCT1116 cell-derived tumor)
Dosage:60 mg/kg body weight
Administration:Subcutaneously; once a day for 11 days
Result:Significantly reduced tumor volume.
体外研究：
PTC-209 (0.01-10 μM; 24-72 hours) induces a concentration- and time-dependent decrease in the cellular viability of all cell lines tested.PTC-209 (1-2.5 μM) inhibits STAT3 phosphorylation in A549 lung cancer cells and MDA-MB-231 breast cancer cells.
PTC-209 hydrobromide is a specific BMI-1 inhibitor with an IC50 of 0.5 μM in HEK293T cell line. PTC-209 hydrobromide irreversibly impairs colorectal cancer-initiating cells (CICs). PTC-209 hydrobromide shows potent anti-myeloma activity and impairs the tumor microenvironment.
体内研究：
PTC-209 (60 mg/kg body weight; subcutaneously; once a day for 11 days) significantly reduces tumor volume.Animal Model:Nude mice (male, aged 8-10 weeks, HCT1116 cell-derived tumor)
Dosage:60 mg/kg body weight
Administration:Subcutaneously; once a day for 11 days
Result:Significantly reduced tumor volume.
体外研究：
PTC-209 (0.01-10 μM; 24-72 hours) induces a concentration- and time-dependent decrease in the cellular viability of all cell lines tested.PTC-209 (1-2.5 μM) inhibits STAT3 phosphorylation in A549 lung cancer cells and MDA-MB-231 breast cancer cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备